Evidence in Action
Innomagine is born digital next gen solution provider powered by AI enabling platform
This is how we make science matter from lab discovery to real-life outcomes.
We work across 425+ products from discovery to maturity and across 100+ therapy area indications.
Our Case studies
Case Study 01
Publication Strategy for first-in-class novel medicine for a Rare Disease
A small biotechnology firm, previously inexperienced in publication strategies, was tasked with shaping a publication plan for a novel first-in class medicine targeting a rare disease. The objective was to build awareness around the disease, introduce novel therapeutic approaches, and highlight biomarkers indicating treatment efficacy.
Challenge
The biotech's major hurdles included a lack of expertise in developing a robust publication strategy with a limited knowledge of disease area and overwhelming volume of citations (~7000) in last 5 year. The challenges were how to categorise these citations, identify gaps, journals and conferences to target, and cadence of publications and presentations over a period across geographies.
Strategy/Methodology
To address these challenges, the team utilized Evidence Eagle® to systematically categorize citations by meta-data and visually analyse the evidence. This approach revealed hidden gaps and opportunities, allowing for a scientifically grounded strategy that offered actionable insights beyond subjective opinions.
Action
The findings guided the creation of a strategic publication plan:
Identification of Target Journal and Conferences: Pinpointing top journals and conferences ideal for reaching target audience.
Focus Areas: Prioritizing research and publication efforts on underrepresented themes to maximize impact and visibility.
Audience Engagement: Tailoring communications to educate and engage specific segments of audience.
Results
The strategic approach not only positioned the biotech as a thought leader in the field but also significantly enhanced the visibility of the novel treatment among key stakeholders.
Impact
The publication strategy led to a series of well-received articles and presentations, notably at high-impact conferences and in leading scientific journals. This not only advanced the understanding and recognition of the rare disease but also placed the biotech firmly on the map as an innovator in disease treatment research.
